The evidence does not support promising that a course of tesamorelin permanently removes visceral fat. It also does not justify telling every individual that all fat must return on an identical timetable, regardless of subsequent circumstances.
In the randomized trial with a safety extension, some participants continued tesamorelin while others switched to placebo after the initial phase. The group switching to placebo lost the initial visceral-fat improvement. That is meaningful evidence about durability in the studied HIV population.
A group result is not an individual forecast
The finding indicates that benefit was not maintained simply by having previously received treatment. It does not provide a personalized prediction for someone using a different formulation, living with different conditions or changing other aspects of care.
Maintenance and withdrawal are also different concepts. A return of the measured condition does not automatically mean dependence, a dangerous withdrawal syndrome or permanent damage to hormone production. Those are separate claims requiring their own evidence.
Anecdotes about keeping a smaller waist do not directly refute the trial unless the same compartment is measured comparably. Changes in body weight, abdominal appearance and consumer device scores may tell different stories. The measurement should stay attached to the conclusion.
The useful clinical discussion concerns expected benefit, how response is assessed, what happens when treatment changes, and how the overall care plan is reviewed. An online article cannot decide whether an individual should continue or stop a prescribed medicine.
This research also does not validate a cycling schedule or a stack intended to prevent regain. A proposed maintenance strategy would need its own controlled evidence, including safety and durability.
For readers, the balanced conclusion is that continued benefit cannot be assumed after discontinuation, while exact personal outcomes remain uncertain. Decisions about prescribed tesamorelin should be made with the treating clinician rather than with a universal forum rule about stopping, restarting or making the effect permanent.